SMARCA1 and breast carcinoma: However, according to a study by Dai et al., SMARCA1 downregulation is associated with poorer prognosis in breast cancer patients, which warrants further investigation into its role in breast cancer prognosis (Ye et al., 2009; Dai et al., 2022).